MREO Stock Forecast & Price Target

Mereo BioPharma Group is showing potential for strong future growth as their two rare disease product candidates, setrusumab and alvelestat, have shown strong statistical significance in clinical trials. Despite not meeting their primary endpoints, the improvement in bone mineral density (BMD) and positive patient reported outcomes for setrusumab provides a potential path to market, especially with the FDA's endorsement of BMD as a valid surrogate endpoint for osteoporosis. With a strong cash position and European and FDA designations, Mereo BioPharma Group is well-positioned for success in the rare disease market.

Mereo BioPharma Group is an established UK-based biopharmaceutical company facing the standard risks of the industry including unexpected outcomes from clinical trials, regulatory uncertainty, and a competitive and price-sensitive market for its rare disease product candidates. While their setrusumab treatment for osteogenesis imperfecta showed promising results in BMD improvement, it failed to meet its primary endpoint of reducing fractures. With a lower probability of success and the removal of their alvelestat treatment for AATD from our valuation, our outlook on Mereo BioPharma's stock is negative.